37 related articles for article (PubMed ID: 38685176)
1. Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC.
Hines JB; Cameron RB; Esposito A; Kim L; Porcu L; Nuccio A; Viscardi G; Ferrara R; Veronesi G; Forde PM; Taube J; Vokes E; Bestvina CM; Dolezal JM; Sacco M; Monteforte M; Cascone T; Garassino MC; Torri V
J Thorac Oncol; 2024 Mar; ():. PubMed ID: 38461929
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.
Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L
Front Immunol; 2024; 15():1359302. PubMed ID: 38646542
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Chemo-Immunotherapy for Early-Stage Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Banna GL; Hassan MA; Signori A; Giunta EF; Maniam A; Anpalakhan S; Acharige S; Ghose A; Addeo A
JAMA Netw Open; 2024 Apr; 7(4):e246837. PubMed ID: 38625698
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
Hoon SN; Lau PK; White AM; Bulsara MK; Banks PD; Redfern AD
Cochrane Database Syst Rev; 2021 May; 5(5):CD011220. PubMed ID: 34037241
[TBL] [Abstract][Full Text] [Related]
5. Association of pathological response with long-term survival outcomes after neoadjuvant immunotherapy: A meta-analysis.
Wei C; Sun H; Hu J; Ma Z; Cao B
Int Immunopharmacol; 2024 May; 133():112078. PubMed ID: 38685176
[TBL] [Abstract][Full Text] [Related]
6. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Cortazar P; Zhang L; Untch M; Mehta K; Costantino JP; Wolmark N; Bonnefoi H; Cameron D; Gianni L; Valagussa P; Swain SM; Prowell T; Loibl S; Wickerham DL; Bogaerts J; Baselga J; Perou C; Blumenthal G; Blohmer J; Mamounas EP; Bergh J; Semiglazov V; Justice R; Eidtmann H; Paik S; Piccart M; Sridhara R; Fasching PA; Slaets L; Tang S; Gerber B; Geyer CE; Pazdur R; Ditsch N; Rastogi P; Eiermann W; von Minckwitz G
Lancet; 2014 Jul; 384(9938):164-72. PubMed ID: 24529560
[TBL] [Abstract][Full Text] [Related]
7. Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis.
Huang M; O'Shaughnessy J; Zhao J; Haiderali A; Cortés J; Ramsey SD; Briggs A; Hu P; Karantza V; Aktan G; Qi CZ; Gu C; Xie J; Yuan M; Cook J; Untch M; Schmid P; Fasching PA
Cancer Res; 2020 Dec; 80(24):5427-5434. PubMed ID: 32928917
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant treatment for stage III and IV cutaneous melanoma.
Gorry C; McCullagh L; O'Donnell H; Barrett S; Schmitz S; Barry M; Curtin K; Beausang E; Barry R; Coyne I
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012974. PubMed ID: 36648215
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer.
Huang M; O'Shaughnessy J; Zhao J; Haiderali A; Cortes J; Ramsey S; Briggs A; Karantza V; Aktan G; Qi CZ; Gu C; Xie J; Yuan M; Cook J; Untch M; Schmid P; Fasching PA
J Natl Compr Canc Netw; 2020 Aug; 18(8):1096-1104. PubMed ID: 32755985
[TBL] [Abstract][Full Text] [Related]
10. Association between event-free survival and overall survival in early-stage triple-negative breast cancer.
Huang M; Fasching PA; Haiderali A; Xue W; Pan W; Karantza V; Yang F; Truscott J; Xin Y; O'Shaughnessy J
Future Oncol; 2024 Feb; 20(6):335-348. PubMed ID: 37602372
[No Abstract] [Full Text] [Related]
11. Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysis.
Ostoros G; Hettle R; Georgoulia N; Berktas M; Chander P; Diaz Perez I; Couto AM; Eichinger C; Field P; Morten P
Expert Rev Anticancer Ther; 2023; 23(12):1305-1313. PubMed ID: 37850939
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
